Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tivic Health Systems ( (TIVC) ) has issued an update.
On May 15, 2025, Tivic Health Systems announced its financial results for the first quarter ending March 31, 2025, and highlighted significant strategic shifts, including an expanded clinical pipeline. The company secured a worldwide exclusive licensing agreement for Entolimod and Entolasta, aimed at treating acute radiation syndrome, and engaged with the White House and FDA to explore military applications. Tivic also reported advancements in its non-invasive vagus nerve stimulation program and secured financing agreements to support its transformation strategy. Financially, the company saw a decline in revenue due to reduced sales of its ClearUP device, while maintaining a stable gross margin and operating expenses compared to the previous year.
Spark’s Take on TIVC Stock
According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.
The overall stock score of 43 reflects Tivic Health Systems’ current financial difficulties, including declining revenues and negative profitability. However, recent strategic initiatives and corporate events provide some optimism for future growth. The stock’s technical indicators and valuation remain weak, necessitating significant improvements in financial performance and market sentiment to enhance stock attractiveness.
To see Spark’s full report on TIVC stock, click here.
More about Tivic Health Systems
Tivic Health Systems, Inc. is a diversified immunotherapeutics company focused on harnessing the immune and autonomic nervous systems to combat disease and restore health. The company develops personalized non-invasive therapeutic devices for vagus nerve stimulation to improve outcomes in inflammatory, neurologic, and cardiac diseases. Tivic Health’s biopharmaceutical program is advancing the toll-like receptor 5 drugs Entolimod and Entolasta, with a focus on treating acute radiation syndrome.
Average Trading Volume: 1,309,386
Technical Sentiment Signal: Sell
Current Market Cap: $3.4M
For detailed information about TIVC stock, go to TipRanks’ Stock Analysis page.